Behind the news
This section aims to provide detailed and transparent overviews of issues relating to the TGA.
Articles that appear here may be of particular interest to the community, or in response to subjects that have received media attention.
If you would like to see particular issues addressed in this section, please let us know by emailing email@example.com or calling 1800 020 653.
Listed medicines: The role of Australia's medicines regulator
27 June 2013: Different types of medicines are regulated in different ways by the Therapeutic Goods Administration, depending on what they contain and how they are to be used
Cough and cold medicines for children - changes
26 November 2012: Advice to consumers and health professionals on cough and cold medicines for children
Concerns with urogynaecological surgical mesh implants
16 October 2012: Urogynaecological surgical mesh implants are used in some surgical procedures to treat the symptoms of pelvic organ prolapse and stress urinary incontinence
Urogynaecological surgical mesh implants - statement provided to the 7.30 Report (ABC) by the TGA
16 October 2012: Statement provided to the 7.30 Report (ABC) by the TGA
Registration of Mifepristone Linepharma (RU 486) and GyMiso (misoprostol)
30 August 2012: The drugs for medical termination of pregnancy, Mifepristone Linepharma (RU 486) and GyMiso® (misoprostol), have been registered today by the TGA
Interpreting information on the Database of Adverse Event Notifications
3 August 2012: TGA is concerned by a media story that may mislead consumers and could potentially discourage them from receiving influenza vaccinations
The TGA decision to ban DMAA
3 August 2012: The TGA has banned the use of the chemical 1,3-dimethylamylamine (DMAA)
Why hasn't the TGA taken Stilnox off the market?
6 July 2012: As the medicines' watchdog, the TGA, has been closely monitoring the sleeping drug, zolpidem (Stilnox) for many years
TGA committee members must declare conflict of interest
9 December 2011: Members of TGA statutory expert advisory committees are required to declare any conflict of interest, whether financial or non-financial
The regulation of medical devices
18 November 2011: Information on the regulation of medical devices
The TGA and the USA FDA agree about problems at CSL Biotherapies
8 July 2011: The TGA wishes to clarify some aspects of this action and what it means for public safety
Evaluation of a new medicine - The TGA's lifecycle approach to regulation
30 June 2011: The TGA aims to ensure that the community has access to therapeutic advances within a reasonable timeframe
CSL Biotherapies: 'Warning Letter' issued by the United States' Food and Drug Administration
24 June 2011: The United States' Food and Drug Administration (FDA) has issued a 'Warning Letter' to CSL Biotherapies (CSL) following their audit of CSL's manufacturing facility
Recall of DePuy Orthopaedics ASR hip replacement device
16 May 2011: Australia was the first country in the world to take regulatory action to ensure the removal of the DePuy ASR hip replacements from the market
Complementary medicines: the regulatory framework
13 May 2011: How complementary medicines are regulated in Australia
Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children
8 October 2010: In Australia, vaccines and other prescription medicines are regulated by the TGA in accordance with the provisions of the Therapeutic Goods Act 1989.
Web page last updated: Friday, 29 November 2013